Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 µg dose level may be considered in people aged 18 years and older at least six months after completion of the primary series.
“This recommendation is supported by clinical evidence that a 50 µg booster dose induces a strong immune response against COVID-19. We thank the EMA and the CHMP for their review,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We believe that mRNA vaccines are well-positioned to adapt to the evolving epidemiology of SARS-CoV-2. We are grateful for the opportunity to provide individuals in the EU with another layer of protection.” (ILKHA)